All In Biotech

Drug Trial Radar · NCT05469854

A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate

A Phase I Trial to Investigate the Pharmacokinetics and ECG Effects of Single Doses of Linaprazan Glurate Administered as Oral Tablets to Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

121

Planned (sponsor's estimate)

Start

Jul 13, 2022

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Cinclus Pharma Holding ABIndustry
Sponsor type
Industry
First posted
Jul 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate. The trial will explore the PK properties of linaprazan glurate and linaprazan as well as the cardiodynamic ECG effects, safety, and tolerability after the administration of single doses: 300 mg and 600 mg in Part I of the trial, using formulation A of linaprazan glurate, as well as 150 mg, 275 mg, and up to 2 additional dose levels, using formulation C of linaprazan glurate to reach target linaprazan mean Cmax exposure (5222 nmol/L).

Conditions

  • Pharmacokinetics
  • Cardiodynamic ECG
  • Safety, and Tolerability
  • GERD

Interventions

  • Linaprazan glurateDrug

    Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses). Linaprazan glurate hydrochloride (HCl), 25 mg and 50 mg (as base) oral tablets (150 mg, 275 mg and up to 2 additional dose levels).

  • PlaceboDrug

    Single dose, oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUCinf)Time frame: Up to 24 hours
  2. Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUClast)Time frame: Up to 24 hours
  3. Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (Cmax)Time frame: Up to 24 hours
  4. Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (T1/2)Time frame: Up to 24 hours
  5. Measurement of Cardiodynamic ECG (QTcF)Time frame: Up to 24 hours
  6. Measurement of Cardiodynamic ECG (heart rate)Time frame: Up to 24 hours
  7. Measurement of Cardiodynamic ECG (PR interval)Time frame: Up to 24 hours
  8. Measurement of Cardiodynamic ECG (QRS interval)Time frame: Up to 24 hours
  9. Measurement of Cardiodynamic ECG (placebo-corrected QTcF)Time frame: Up to 24 hours
  10. Measurement of Cardiodynamic ECG (placebo-corrected heart rate)Time frame: Up to 24 hours
  11. Measurement of Cardiodynamic ECG (placebo-corrected PR interval)Time frame: Up to 24 hours
  12. Measurement of Cardiodynamic ECG (placebo-corrected QRS interval)Time frame: Up to 24 hours
  13. Measurement of Cardiodynamic ECG (categorical outliers)Time frame: Up to 24 hours
  14. Measurement of Cardiodynamic ECG (changes of T-wave)Time frame: Up to 24 hours
  15. Measurement of Cardiodynamic ECG (changes of U-wave)Time frame: Up to 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CTC Clinical Trial Consultants AB

    Uppsala, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.